ArticleOncology letters2026
Prognostic effect and prognostic factors of TACE for the treatment of unresectable hepatocellular carcinoma: Propensity score matching analysis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a global challenge due to its high morbidity and mortality as well as its adverse response to treatment. Transcatheter arterial chemoembolization (TACE) is widely used in the treatment of unresectable (u)HCC. However, no consensus has been reached regarding the optimal number of TACE sessions for uHCC. The present study aimed to evaluate the prognostic value of TACE treatment frequency in patients with uHCC and identify factors affecting prognosis. Data were collected from patients with HCC treated with TACE in Hebei General Hospital (Shijiazhuang, China) between January 2017 and December 2023. Patients were divided into three groups based on number of TACE treatments: TACE 1 (one time), 2 (two times) and 3 (≥3 times). The outcomes assessed included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety profiles. The propensity score matching was used to decrease the influence of confounding factors on the outcomes. The best ORR in the TACE 1, 2 and 3 groups was 29.6, 77.8 and 44.4%, respectively (P=0.001); the best DCR was 66.7, 88.9 and 96.3% (P=0.016); median PFS was 5, 14 and 22 months (P=0.0034) and median OS was 8, 21 and 26 months (P=0.0028). No significant differences were observed between groups regarding grade 1/2 adverse events. Hypertension, number of TACE sessions, adverse reactions, targeted therapy/immunotherapy and Barcelona Clinic Liver Cancer (BCLC) stage were independent prognostic factors for PFS; similarly, carbohydrate antigen 199 levels, number of TACE sessions, adverse reactions and BCLC stage were independent prognostic factors for OS. Compared with a single TACE session, two or three TACE sessions were associated with significantly prolonged PFS and OS times; however, no further improvement was observed beyond three sessions. Within the range of one to three TACE sessions, an increased number of TACE sessions was associated with prolonged PFS and OS times, improved prognosis and a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.